bioAffinity Technologies, Inc. (NASDAQ:BIAF) Short Interest Update

bioAffinity Technologies, Inc. (NASDAQ:BIAF) saw a large decline in short interest in the month of January. As of January 31st, there was short interest totalling 396,800 shares, a decline of 7.2% from the January 15th total of 427,500 shares. Based on an average daily trading volume, of 172,600 shares, the short-interest ratio is presently 2.3 days. Approximately 4.2% of the company’s shares are short sold.

bioAffinity Technologies Trading Up 0.6 %

Shares of BIAF stock traded up $0.01 on Monday, reaching $0.81. 42,286 shares of the stock were exchanged, compared to its average volume of 298,197. The company has a quick ratio of 1.01, a current ratio of 1.02 and a debt-to-equity ratio of 0.18. The stock has a market cap of $12.55 million, a P/E ratio of -0.98 and a beta of 2.95. The firm has a 50 day moving average of $0.85 and a two-hundred day moving average of $1.33. bioAffinity Technologies has a 1-year low of $0.57 and a 1-year high of $3.62.

Institutional Investors Weigh In On bioAffinity Technologies

A hedge fund recently raised its stake in bioAffinity Technologies stock. Sheaff Brock Investment Advisors LLC grew its position in bioAffinity Technologies, Inc. (NASDAQ:BIAF) by 131.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 46,304 shares of the company’s stock after purchasing an additional 26,304 shares during the period. Sheaff Brock Investment Advisors LLC owned approximately 0.30% of bioAffinity Technologies worth $42,000 as of its most recent SEC filing. 1.64% of the stock is owned by hedge funds and other institutional investors.

About bioAffinity Technologies

bioAffinity Technologies, Inc, a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level.